Serum antibodies to *Legionella* agents in bronchial asthma

S BEER, I BOLDUR, R KAZAK, S AVIDAN, AND Y KANNAI

**Paediatric Pulmonary-Allergic Service, Department of Microbiology, Assaf Harofeh Medical Center, Sackler School of Medicine, Tel Aviv; and Department of Theoretical Mathematics, Weizman Institute of Science, Rehovot, Israel**

**SUMMARY** The prevalence of seropositivity to *Legionella* species was studied in 184 children with bronchial asthma and 80 control children, age and sex matched, without respiratory tract infections. The sera were examined by indirect immunofluorescence with antigens of six *Legionella* species. The asthmatic children showed a significantly high percentage of seroreactions to *L. pneumophila* compared with the control children. In the asthmatic children, no association was found between age, sex, onset of asthmatic symptoms, living conditions, corticosteroid treatment, or exposure to aerosols and seropositivity to *Legionella*. No relation could be found between the asthma severity score and the titre of serum antibodies to *L. pneumophila*.

None of the 32 sera with titres of 1:256 or higher were reactive for *Legionella* specific IgE antibodies.

A high prevalence of antibodies to *L. pneumophila* was found in children suffering bronchial asthma. Further studies are necessary to clarify the clinical relevance.

Since the aetiological agent of legionnaires’ disease was first described in adult patients in 1975, a few cases have been reported in childhood. In a previous survey from our hospital, three of 167 children admitted to hospital for acute respiratory infections, had antibody titres of 1:256 or more to *Legionella* species at the time of admission; one of these children had asthma. Respiratory tract infections have a particularly important impact upon children with asthma. Recently antibody titres of 1:256 or higher to *L. pneumophila* were reported in 29-4% of children with cystic fibrosis. A study of 113 adults suffering from chronic pulmonary diseases, including 41 with bronchial asthma, showed a significant increase of serum antibodies to *L. pneumophila*.

This study was designed to determine whether asthmatic children show a higher incidence of seropositivity to *Legionella* species compared with non-asthmatic children. Precipitating asthma attacks in children are often associated with symptoms that may be clinically regarded as evidence of upper or lower respiratory infections, but while the role of viral infections in precipitating asthma attacks is already well established, the role of bacterial infections is not yet clear.

As far as we know, this is the first prevalence study of antibodies to *Legionella* species in children with bronchial asthma.

**Patients and methods**

**Study population.** Serum samples were collected during one year (August 1982 to August 1983) from 184 asthmatic children attending the outpatient clinic of the Paediatric Pulmonary-Allergic Service regularly.

The sera were obtained when blood was drawn for other diagnostic examinations. All children were suffering from bronchial asthma according to the criteria of the American Thoracic Society. A total of 134 children had perennial extrinsic allergic asthma and 50 had seasonal allergic extrinsic bronchial asthma. All the specimens were collected when the children were free of symptoms. Of the 184 children, 118 (64.14%) were boys and 66 (35.86%) were girls; their ages ranged from 2 to 15 years (mean 8.3 years). The first asthmatic attack had occurred in 56.5% of the patients three or more years before the examination, and in 29.1% of the patients one to two years earlier. The parents were asked to answer a standardised questionnaire on the
severity of asthma during the preceding year. An asthma severity score from 1 to 14 was computed for each child, as described by Murray et al. Additional information gathered included the number of past admissions to hospital, previous use of mist tents or drug administration by aerosols, and mean age from onset of symptoms. Although corticosteroid treatment is one of the asthma severity score’s features, it was considered separately also, because of its particular importance in legionnaires’ disease.

Eighty children suffering from various non-respiratory disorders, or surgical patients, age and sex matched with the study group, served as controls. The study was possible because blood was drawn for other routine examinations; however, informed consent was obtained from the parents of both the study and the control group.

**Laboratory tests.** The serum samples were stored at −20°C until examined by the indirect immunofluorescence assay. Antigens and positive antisera for standardisation were obtained from the Centers for Disease Control, USA, and represented *L. pneumophila*, gr 1–4 (monovalent and pool); *L. pneumophila*, gr 5–6 (monovalent and pool); *L. longbeachae*, gr 1–2 (pool); and *L. m. gormanii*, *L. dumoffii*, and *L. bozemanii*. The immunofluorescence assay was examined according to the technique of the Centers for Disease Control (1981), with the exception that the first screening was performed with a commercial conjugate (Institute Pasteur, Paris) fluorescein isothiocyanate antihuman gammaglobulin (Ig), and those positive to a titre of 1:256 or more were examined again after absorption with antigen of *Escherichia coli* 013:k92:H4. This procedure excluded eight sera (19.5%) from the group positive to a titre of 1:256 or more, as their titres after absorption were 1:128. Sera positive to 1:256 or more with fluorescent rabbit anti-Ig were examined further for IgG- and IgM-type antibodies with fluorescein isothiocyanate antihuman IgG (antigamma) and antihuman IgM (antimú) (Wellcome Reagents). The two sera positive for IgM were absorbed on a column of polymerised human IgG to avoid false reactions due to rheumatoid factors. Only one of them was refractory to this treatment and is considered positive to IgM. The positive sera with titres of 1:256 or higher were also examined for antibodies to *Chlamydia*, *Mycoplasma*, and *Pseudomonas aeruginosa* serogroup H11 to rule out false positive reactions. The complement fixation test for *Chlamydia* and *Mycoplasma* was performed by the Public Health Laboratories at Abu Kabir. *Pseudomonas* antibodies were tested by immunofluorescent assay with goat antihuman IgG (γ chain specific) fluorescein isothiocyanate conjugate, affinity chromatography purified (Sigma Chemical, USA). One child had low titres for *Chlamydia* (1:120) and *Mycoplasma* (1:60). Three children had a titre of 1:64 for *P. aeruginosa*; these results probably did not interfere with the titres to *Legionella*.

All the sera with titres of 1:256 or more were tested for IgE specific antibodies to *L. pneumophila*. We used the immunofluorescent assay first, performed as described for IgG and IgM. Goat antihuman IgE (γ chain specific) fluorescein isothiocyanate conjugate was from Miles Yeda, Israel. This antisera was absorbed before use with a mixture of formalin-killed *L. pneumophila* cells, serogroup 1–4, because it cross reacted with *L. pneumophila*.

The tests for specific IgE for *L. pneumophila* were performed by two enzyme linked immunoassays (ELISA) because we were not in possession of a positive control. The first system was as described by Farshy. The plates used were from Dynatech (M/129/B). They were coated with soluble *L. pneumophila* serogroup 1–4 antigen. Horse radish peroxidase conjugated to goat antihuman IgE (heavy chain specific) was from Miles Yeda, Israel. The results were read spectrophotometrically at 492 nm with a Gilford (2600) spectrophotometer. The second ELISA system used was part of the Platelia total IgE kit for the quantitative determination of total IgE in human serum (Institute Pasteur, Paris). The kit was used as recommended by the manufacturer, in addition to the coated plate method, described above.

**Results**

The seroreactions of the study groups to *L. pneumophila* are summarised in Table 1. Significantly more asthmatic children were seroreactive to *Legionella* antigens. The *χ²* test was used for statistical analysis. Thirty two (17.4%) asthmatic children and only one (1.25%) of the children from the control group had titres of 1:256 or more (P<0.001). Four children of the 32 had titres of 1:512. One of them reacted with IgM at 1:256. Thirty seven (20.11%) of the asthmatic children had a titre of 1:128 compared with four (5%) in the control group (P<0.01). Eighty five (46.1%) of the asthmatic children had titres of 1:64 compared with 15 children (18.75%) in the control group (P<0.005). Thirty (16.3%) of the asthmatic and 60 (75%) of the control group children, had titres of less than 1:64.

The differences between the frequency of given titres of the asthmatic children versus the healthy children are shown in Fig. 1. The cumulative
Serum antibodies to Legionella agents in bronchial asthma

Table 1  Seroreactions to Legionella pneumophila

<table>
<thead>
<tr>
<th>No examined</th>
<th>Titre</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>≥1:256</td>
</tr>
<tr>
<td>Asthmatic children</td>
<td>184</td>
</tr>
<tr>
<td>Control group</td>
<td>80</td>
</tr>
</tbody>
</table>

P* calculated by χ² test.

In the asthmatic children, the serological titres were unrelated to age and sex. The mean age and mean age in years from the onset of symptoms are shown in Table 2. The percentage of children with perennial asthma was more or less constant in each titre group. No association was found between the mean number of years from the onset of the first asthmatic symptoms and the titre group (Table 2).

Using the asthma history scores versus the titre of serum antibodies to *L. pneumophila*, a regression line, based on all the observations, was computed with the Statistical Analysis System (SAS) general model's procedure (Fig. 3). The significance level of the intercept is 0.0001 and the slope 0.0003. The correlation coefficient r=0.265.

The 32 sera with titres of 1:256 or more were tested further for IgE specific anti-*Legionella* antibodies. None of those sera was found reactive by any of the three methods performed. No difference was found between patients with high or low concentrations of IgE.

![Fig. 1](image1.png)  
Fig. 1  Frequencies of given titres for the asthmatic and the control children.

![Fig. 2](image2.png)  
Fig. 2  Cumulative distributions of the frequencies of given titres for the asthmatic and the control children.
Our results are highly significant calculated by either $\chi^2$ test (Table 1) or Smirnov test, which detects discrepancies between two empirical distribution functions. Seropositivity to Legionella belonging to groups other than L pneumophila was very low in our study groups, therefore we analysed statistically only the seroreactions to this.

Previous studies have shown increases in antibody titres during convalescence from legionellosis that were specific for a single serogroup antigen or against antigens common in multiple serogroup strains. The seropositive sera in our study cross reacted with the individual antigens belonging to L pneumophila with relatively high frequency; as in the other prevalence studies performed in our area. It has been proposed, but not proved, that the common antigen reactions may be secondary reactions on repeat exposure to a different serogroup strain. An analysis of the accumulated data on the asthmatic group of children showed no relation between the mean age or between the mean number of years from the onset of the first asthmatic symptoms and the titre group (Table 2).

The correlation coefficient obtained between the asthma severity score and the antibody titre to L pneumophila from the regression line in Fig. 3, is small ($r=0.265$), that means that there is a very high variability in the data.

Legionnaires’ disease pneumonia is acquired mainly by inhalation of aerosols, from waterborne environmental sources, as condensate from air cooling systems, or central air conditioning systems. None of the asthmatic children lived in such conditions. The association found between serological titres and number of past admissions to hospital, exposure to aerosols in the emergency room, or number of lower respiratory tract infections among the asthmatic children is poor.

Corticosteroid treatment, one of the score’s features, is considered to be one of the predisposing factors in legionnaires’ disease, but no relation was found between corticosteroid treatment alone and the titre group of the asthmatic children. In a study of 41 adult patients with asthma, 20% had raised antibody titres against L pneumophila. This prevalence of titres of 1:64 or more among patients
with asthma was not associated with corticosteroid treatment. In another study of young adults with cystic fibrosis, no relation was found between the presence of raised antibody titres to *Legionella* and corticosteroid treatment.

We have no evidence that the higher seroreactivity of the asthmatic children is due to their higher susceptibility to infection with *Legionella*. An explanation for the high incidence of seropositivity to *Legionella* in asthmatic children, could be overactivity of the immune system reflected by raised immunoglobulin concentrations, especially IgE. Using three different techniques, no serum IgE antibodies in *Legionella* antibodies were detected in the 32 sera with titres equal to or higher than 1:256. No correlation was found between the antibody titre to *Legionella* and the concentration of total serum IgE of the asthmatic children.

We could not obtain any reference to this subject through the computerised Allergy Service Pharmacia Information Program. The incidence of IgE antibodies in bacterial disease is not well documented. Some authors claim that bacterial infections play little role in precipitating asthma attack. Others found IgE antibodies to *Haemophilus influenzae* and *Streptococcus pneumoniae*, and therefore conclude that immediate hypersensitivity to bacteria may play a role in the infectious exacerbations of bronchial asthma. Some authors suggest that IgE antibacterial antibodies appear early in the course of infectious disease, somewhat later than IgM but earlier than IgG antibodies. This could be the reason why we did not find positive sera for IgE specific to *Legionella*. The sera were collected from the asthmatic patients in intervals between the asthmatic attacks and not immediately after a mild or acute respiratory disease.

One case of legionnaires’ disease associated with severe bronchospasm and hyperventilation was reported in an adult patient. Further studies are necessary to prove the role of *Legionella* in infections during exacerbations of asthma.

It should, however, be kept in mind that asthma patients have long term contact with the infected hospital environment, either as outpatients or as inpatients; they are often treated with corticosteroids which have an immunosuppressive character and are frequently inhaling medications through aerosols which are recognised sources for legionnaires’ disease. All these together lead to a continuous exposure of asthmatic children to *Legionella* and could be a contributing factor for their higher incidence in seropositivity than healthy children.

Many febrile respiratory diseases in asthmatic children remain without a differential diagnosis.

The high prevalence of positive seroreactions to *Legionella* antigens described in our study indicates that *Legionella* infections should be considered in diagnosis and treatment.

We thank the chief nurses L Cohen, E Bonda, and Y Baruch for their kind cooperation, and Mrs J Szichman for the secretarial help.

References

Beer, Boldur, Kazak, Avidan, and Kannai


Correspondence to Dr S Beer. Paediatric Pulmonary-Allergic Service, Assaf Harofeh Medical Center, Zerifin 70300, Israel.

Received 14 November 1984
Serum antibodies to Legionella agents in bronchial asthma.

S Beer, I Boldur, R Kazak, S Avidan and Y Kannai

*Arch Dis Child* 1985 60: 225-230
doi: 10.1136/adc.60.3.225

Updated information and services can be found at:
http://adc.bmj.com/content/60/3/225

*These include:*

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/